Annual Drug Patent Expirations for EXFORGE+HCT
Exforge Hct is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and two Paragraph IV challenges.
EXFORGE HCT drug price trends.
Drug patent litigation for EXFORGE HCT.
This drug has thirty-four patent family members in twenty-nine countries.
The generic ingredient in EXFORGE HCT is amlodipine besylate; hydrochlorothiazide; valsartan. One supplier is listed for this compound. Additional details are available on the amlodipine besylate; hydrochlorothiazide; valsartan profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com